Results 151 to 160 of about 5,822 (192)
Teprotumumab for Thyroid-Associated Ophthalmopathy [PDF]
New England Journal of Medicine, 2017 Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the ...
Terry J Smith +2 more
exaly +10 more sources
Radioiodine and thyroid-associated ophthalmopathy [PDF]
Orbit, 1996 Particular attention has recently been paid to the relationship between radioiodine administration and the course of thyroid-associated ophthalmopathy (TAO). Conflicting results have been reported in the literature, and radioiodine therapy has been associated either with aggravation, improvement, or no relevant changes of eye disease.
Claudio Marcocci +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Rituximab for thyroid-associated ophthalmopathy
Cochrane Database of Systematic Reviews, 2022Thyroid-associated ophthalmopathy (TAO) is the most frequent extrathyroidal manifestation of Graves' disease, affecting up to 50% of patients. It has a great impact on quality of life. Rituximab (RTX) is a human/murine chimeric monoclonal antibody that targets the CD20 receptor on B-lymphocytes.
Swan, Kang +3 more
openaire +4 more sources
Glycosaminoglycans in Thyroid-Associated Ophthalmopathy
Autoimmunity, 1992 Glycosaminoglycan (GAG) accumulation in the retrobulbar space of patients with thyroid-associated ophthalmopathy (TAO) has been documented in a number of immunohistochemical studies. In order to gain further insight into possible immunopathogenic mechanisms, the influence of humoral immunity on retrobulbar fibroblasts (RF) as GAG producing cells as ...
C Stover
exaly +4 more sources
Infliximab: A Novel Treatment for Sight-Threatening Thyroid Associated Ophthalmopathy [PDF]
Orbit, 2005 We describe a patient with sight threatening thyroid associated ophthalmopathy (TAO) who was successfully treated with infliximab, an anti-tumour necrosis factor (TNF)-a ...
Philip I Murray
exaly +2 more sources
The pathogenesis of thyroid-associated ophthalmopathy
Journal of Endocrinology, 1989TAO is an autoimmune disease the pathogenesis of which is unclear. Autoimmunity against orbital antigens has been demonstrated, although the precise immunological mechanisms responsible are unidentified. Cytokines probably play an important mediating role.
P, Perros, P, Kendall-Taylor
openaire +2 more sources
Pathogenesis of thyroid-associated ophthalmopathy
Trends in Endocrinology & Metabolism, 1993Thyroid-associated ophthalmopathy is a complex disease whose pathogenesis is thought to be autoimmune. Evidence has accumulated to implicate lymphocytes, antibodies, and cytokines targeting the orbital tissues whose structural and functional characteristics are unique.
P, Perros, P, Kendall-Taylor
openaire +2 more sources
The pathophysiology of thyroid-associated ophthalmopathy
Ophthalmology Clinics of North America, 2002TAO is an inflammatory disease of the orbital tissues. The effects of inflammation, mediated through cytokine release, include proliferation of fibroblasts, increased deposition of extracellular matrix, and adipocyte differentiation and proliferation. As a result, edema, enlargement of the extraocular muscles, and increased volume of the orbital soft ...
Mark P, Hatton, Peter A D, Rubin
openaire +2 more sources
2021 update on thyroid-associated ophthalmopathy
Journal of Endocrinological Investigation, 2021Our understanding of thyroid-associated ophthalmopathy (TAO, A.K.A Graves' orbitopathy, thyroid eye disease) has advanced substantially, since one of us (TJS) wrote the 2010 update on TAO, appearing in this journal.PubMed was searched for relevant articles.Recent insights have resulted from important studies conducted by many different laboratory ...
E. J. Neag, T. J. Smith
openaire +2 more sources